These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24386160)

  • 1. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.
    Terris-Prestholt F; Hanson K; MacPhail C; Vickerman P; Rees H; Watts C
    PLoS One; 2013; 8(12):e83193. PubMed ID: 24386160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current status of the female condom in Africa].
    Deniaud F
    Sante; 1997; 7(6):405-15. PubMed ID: 9503499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
    Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
    J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa.
    Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Kilbourne-Brook M; Mvundura M; Delany-Moretlwe S; Terris-Prestholt F
    Med Decis Making; 2018 Jan; 38(1):120-133. PubMed ID: 28863752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment.
    Quaife M; Eakle R; Cabrera M; Vickerman P; Tsepe M; Cianci F; Delany-Moretlwe S; Terris-Prestholt F
    BMJ Open; 2016 Jun; 6(6):e010682. PubMed ID: 27354071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
    Terris-Prestholt F; Foss AM; Cox AP; Heise L; Meyer-Rath G; Delany-Moretlwe S; Mertenskoetter T; Rees H; Vickerman P; Watts CH
    BMC Infect Dis; 2014 Jan; 14():14. PubMed ID: 24405719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modelling framework for translating discrete choice experiment results into cost-effectiveness estimates: an application to designing tailored and scalable HIV and contraceptive services for adolescents in Gauteng, South Africa.
    Govathson C; Long LC; Russell CA; Moolla A; Pascoe S; Nichols BE
    J Int AIDS Soc; 2023 Jul; 26(7):e26124. PubMed ID: 37463870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating end-users' voices into the development of an implant for HIV prevention: a discrete choice experiment in South Africa and Zimbabwe.
    Browne EN; Manenzhe K; Makoni W; Nkomo S; Mahaka I; Ahmed K; Shapley-Quinn MK; Marton T; Luecke E; Johnson L; van der Straten A; Minnis AM
    BMC Womens Health; 2023 Feb; 23(1):58. PubMed ID: 36765358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.
    Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Why would you promote something that is less percent safer than a condom?': Perspectives on partially effective HIV prevention technologies among key populations in South Africa.
    Rubincam C; Newman PA; Atujuna M; Bekker LG
    SAHARA J; 2018 Dec; 15(1):179-186. PubMed ID: 30360675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women's interest in vaginal microbicides.
    Darroch JE; Frost JJ
    Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative study of obstacles to diaphragm and condom use in an HIV prevention trial in sub-Saharan Africa.
    Kacanek D; Dennis A; Sahin-Hodoglugil NN; Montgomery ET; Morar N; Mtetwa S; Nkala B; Phillip J; Watadzaushe C; van der Straten A;
    AIDS Educ Prev; 2012 Feb; 24(1):54-67. PubMed ID: 22339145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women's attitudes to condoms and female-controlled means of protection against HIV and STDs in south-western Uganda.
    Hart GJ; Pool R; Green G; Harrison S; Nyanzi S; Whitworth JA
    AIDS Care; 1999 Dec; 11(6):687-98. PubMed ID: 10716009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
    J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between contraceptive method choice and beliefs about HIV and pregnancy prevention.
    Galavotti C; Schnell DJ
    Sex Transm Dis; 1994; 21(1):5-7. PubMed ID: 8140490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV prevention in high-risk women in South Africa: condom use and the need for change.
    van Loggerenberg F; Dieter AA; Sobieszczyk ME; Werner L; Grobler A; Mlisana K;
    PLoS One; 2012; 7(2):e30669. PubMed ID: 22363467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community.
    Gafos M; Mzimela MA; Ndlovu HB; McCormack S; McGrath N
    AIDS Care; 2013; 25(5):573-8. PubMed ID: 22971053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment.
    Browne EN; Montgomery ET; Mansfield C; Boeri M; Mange B; Beksinska M; Schwartz JL; Clark MR; Doncel GF; Smit J; Chirenje ZM; van der Straten A
    AIDS Behav; 2020 May; 24(5):1443-1451. PubMed ID: 31696371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.